Investors cheered when Abbott Labs (ABT) announced plans to split itself in two - separating the presumably lower-growth drug business from the device and diagnostics business. While there are still solid reasons for this split, recent clinical data releases may mean that investors should pause before making any quick assumptions on which half is going to be the "better" company.
Continue reading here:
Which Half Of Abbott Is The Real Growth Story?
No comments:
Post a Comment